A US-Based Survey: The Experiences of 1147 CLL Patients This is a synopsis of the research we presented at the 23rd Congress of the European Hematology Association, Stockholm, Sweden.... September 3, 20182018 ConferencesBy Brad Hedrick
NCCN Hematology Congress 2017: Dr. Wierda on CLL (chronic lymphocytic leukemia) patients that progress on ibrutinib Dr. Bill Wierda heads the powerful CLL team at MDACC in Houston, TX that is responsible for much game changing... August 20, 20182017 ConferencesBy Brad Hedrick
ASH 2017: Dr. John Pagel on Quality Improvement in CLL (chronic lymphocytic leukemia) Dr. Pagel is a CLL specialist out of Swedish Hospital, Seattle. WA whom I interviewed at ASH 2017 about a project... August 7, 20182017 ConferencesBy Brian Koffman
ASH 2017: Dr. Adrian Wiestner on Resistance Mechanism in CLL (chronic lymphocytic leukemia) I had the opportunity to interview Dr. Adrian Wiestner from the National Institutes of Health at ASH 2017 in Atlanta GA about... July 30, 20182017 ConferencesBy Brian Koffman
ASH 2017: Dr. Thomas Kipps on the ROR1 Antibody, Cirmtuzumab At ASH 2017 held in December in Atlanta, Dr. Thomas Kipps from the Moore Cancer Center at UCSD in San... July 22, 20182017 ConferencesBy Brian Koffman
Dr. Koffman Reporting from EHA 2018 I thought I would take a break from our ASH interviews and share my observations from the European Hematology Association... July 15, 20182018 ConferencesBy Brian Koffman
ASH 2017: Dr. Adrian Wiestner on Combination Therapy in CLL (chronic lymphocytic leukemia) At ASH 2017, in Atlanta, Dr. Adrian Wiestner who leads the CLL research team at the National Institute of Health spoke... July 8, 20182017 ConferencesBy Brian Koffman
ASH 2017: Dr. Byrd on What We Don’t Know About CLL By John Byrd, MD and Brian Koffman, MD On the last day of ASH (American Society of Hematology) annual meeting... June 28, 20182017 ConferencesBy clladm1n
ASH 2017: Dr. John Byrd on Acalabrutinib for Relapsed and Refractory CLL (chronic lymphocytic leukemia) Dr. John Byrd out of Ohio State University (OSU) had done much of the research on both ibrutinib and acalabrutinib.... June 26, 20182017 ConferencesBy Todd Dennison
ASH 2017: Professor Michael Hallek on Molecular Evolution in CLL and Venetoclax Resistance At the ASH (American Society of Hematology) annual meeting in 2017 held in Atlanta, GA, I had the opportunity to... June 12, 20182017 ConferencesBy Todd Dennison
